The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, and clinical efficacy of psilocybin-assisted therapy for the treatment of PTSD in US Veterans.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 64
Healthy Volunteers: f
View:

• Be a United States Military Veteran

• Have at least a high-school level of education or equivalent (e.g. GED).

• Have a current DSM-5 diagnosis of Post-traumatic Stress Disorder

• Have a CAPS-5 total severity score of ≥23 at baseline

• SSRIs will be allowable so long as participants are on a stable regimen for a period of 3 months.

• Concurrent psychotherapy is allowed if the type and frequency of the therapy has been stable for at least 2 months prior to screening and is expected to remain stable during participation in the study.

• Be medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests

• No use of hallucinogens in the past 3 months and no history of regular or frequent use of hallucinogens

Locations
United States
Texas
Baylor College of Medicine
RECRUITING
Houston
Contact Information
Primary
Lynnette A. Averill, Ph.D.
emerging@bcm.edu
‪(832) 271-6615
Time Frame
Start Date: 2025-01-30
Estimated Completion Date: 2025-08-31
Participants
Target number of participants: 15
Treatments
Experimental: Psilocybin-assisted therapy
Participants will enter a 5-week participation phase, which includes 3 preparatory sessions, 2 dosing days, and 4 integration sessions.
Related Therapeutic Areas
Sponsors
Collaborators: Usona Institute, AIM Youth Mental Health, Texas Department of State Health Services
Leads: Baylor College of Medicine

This content was sourced from clinicaltrials.gov